

# Accepted Manuscript



Impact of regular or extended hemodialysis and hemodiafiltration on plasma oxalate concentrations in patients with end-stage renal disease

Theresa Ermer, Christoph Kopp, MD, John R. Asplin, MD, Ignacio Granja, BS, Mark A. Perazella, MD, Martin Reichel, PhD, Thomas D. Nolin, PharmD, PhD, Kai-Uwe Eckardt, MD, Peter S. Aronson, MD, Fredric O. Finkelstein, MD, Felix Knauf, MD

PII: S2468-0249(17)30151-1

DOI: [10.1016/j.ekir.2017.06.002](https://doi.org/10.1016/j.ekir.2017.06.002)

Reference: EKIR 172

To appear in: *Kidney International Reports*

Received Date: 22 March 2017

Revised Date: 20 May 2017

Accepted Date: 1 June 2017

Please cite this article as: Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F, Impact of regular or extended hemodialysis and hemodiafiltration on plasma oxalate concentrations in patients with end-stage renal disease, *Kidney International Reports* (2017), doi: 10.1016/j.ekir.2017.06.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Title page****Impact of regular or extended hemodialysis and hemodiafiltration on plasma oxalate concentrations in patients with end-stage renal disease****Running title:** Plasma oxalate reduction with HD/HDF

Theresa Ermer<sup>1,2</sup>, Christoph Kopp, MD<sup>1</sup>, John R. Asplin, MD<sup>3</sup>, Ignacio Granja, BS<sup>3</sup>, Mark A. Perazella, MD<sup>2</sup>, Martin Reichel, PhD<sup>1</sup>, Thomas D. Nolin, PharmD, PhD<sup>4</sup>, Kai-Uwe Eckardt, MD<sup>1</sup>, Peter S. Aronson, MD<sup>2,5</sup>, Fredric O. Finkelstein, MD<sup>2</sup>, Felix Knauf, MD<sup>1,2</sup>.

<sup>1</sup> Department of Nephrology and Hypertension, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

<sup>2</sup> Department of Internal Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, USA

<sup>3</sup> Litholink® Corporation, Laboratory Corporation of America® Holdings, Chicago, USA

<sup>4</sup> Department of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, USA

<sup>5</sup> Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, USA

**Correspondence:** Felix Knauf, M.D.

Department of Nephrology and Hypertension

Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)

Schwabachanlage 12

91054 Erlangen, Germany

Tel.: +49-9131-85-39002; FAX.: +49-9131-85-39209

Email: Felix.Knauf@uk-erlangen.de

Download English Version:

<https://daneshyari.com/en/article/8773883>

Download Persian Version:

<https://daneshyari.com/article/8773883>

[Daneshyari.com](https://daneshyari.com)